{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:43:11Z","timestamp":1789728191362,"version":"4.0.1"},"reference-count":63,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00200","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T06:40:52Z","timestamp":1488177652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Cytokine Signatures in Mucocutaneous and Ocular Beh\u00e7et\u2019s Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Giuseppe","family":"Lopalco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orso Maria","family":"Lucherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"issue":"8","key":"B1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJM197908233010811","article-title":"Beh\u00e7et\u2019s syndrome","volume":"301","author":"James","year":"1979","journal-title":"N Engl J Med"},{"issue":"4","key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0049-0172(98)80001-2","article-title":"Beh\u00e7et\u2019s disease","volume":"27","author":"Kaklamani","year":"1998","journal-title":"Semin Arthritis Rheum"},{"issue":"17","key":"B3","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et\u2019s disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"B4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2249.2008.03626.x","article-title":"Involvement of innate immunity in the pathogenesis of intestinal Beh\u00e7et\u2019s disease","volume":"152","author":"Nara","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et\u2019s disease","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"Suppl 1","key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1546-0096-13-S1-P6","article-title":"Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Beh\u00e7et\u2019s disease","volume":"13","author":"Lucherini","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"B7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of Beh\u00e7et\u2019s disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"10","key":"B8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","article-title":"Cytokines and Beh\u00e7et\u2019s disease","volume":"11","author":"Zhou","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"42","key":"B9","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1097\/MD.0000000000001858","article-title":"Putative role of serum Amyloid-A and proinflammatory cytokines as biomarkers for Beh\u00e7et\u2019s disease","volume":"94","author":"Lopalco","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","article-title":"Critical role of IL-21 in modulating Th17 and regulatory T cells in Beh\u00e7et\u2019s disease","volume":"128","author":"Geri","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"B11","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.2174\/0929867322666150209161448","article-title":"Currently used biologic agents in the management of Beh\u00e7et\u2019s syndrome","volume":"22","author":"Saygin","year":"2015","journal-title":"Curr Med Chem"},{"issue":"4","key":"B12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.autrev.2009.10.005","article-title":"Etiopathogenesis of Beh\u00e7et\u2019s disease","volume":"9","author":"Mendoza-Pinto","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"4","key":"B13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/030097402320318387","article-title":"Cytokine profile in Beh\u00e7et\u2019s disease patients. Relationship with disease activity","volume":"31","author":"Hamzaoui","year":"2002","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"B14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","article-title":"Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease","volume":"128","author":"Geri","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"B15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00005-015-0362-x","article-title":"Targeting Th17 effector cytokines for the treatment of autoimmune diseases","volume":"63","author":"Yamagata","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"9","key":"B16","doi-asserted-by":"publisher","first-page":"e1001395","DOI":"10.1371\/journal.pbio.1001395","article-title":"IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation","volume":"10","author":"Corvaisier","year":"2012","journal-title":"PLoS Biol"},{"issue":"6","key":"B17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/bjd.14376","article-title":"Clinical significance of serum YKL-40 in Beh\u00e7et disease","volume":"174","author":"Seo","year":"2016","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1475-2840-8-61","article-title":"YKL-40 an emerging biomarker in cardiovascular disease and diabetes","volume":"8","author":"Camilla","year":"2009","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"B19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.chom.2012.05.017","article-title":"Chitinase 3-like-1 promotes Streptococcus pneumoniae killing and augments host tolerance to lung antibacterial responses","volume":"12","author":"Dela Cruz","year":"2012","journal-title":"Cell Host Microbe"},{"issue":"1","key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-003-0400-6","article-title":"Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Beh\u00e7et\u2019s disease","volume":"25","author":"D\u00fczg\u00fcn","year":"2005","journal-title":"Rheumatol Int"},{"issue":"2","key":"B21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/03009740701747137","article-title":"Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Beh\u00e7et\u2019s disease","volume":"37","author":"Turan","year":"2008","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"B22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1189\/jlb.0410217","article-title":"gp130 at the nexus of inflammation, autoimmunity, and cancer","volume":"88","author":"Silver","year":"2010","journal-title":"J Leukoc Biol"},{"issue":"3","key":"B23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s10165-012-0694-x","article-title":"Serum level of APRIL\/BLyS in Beh\u00e7et\u2019s disease patients: clinical significance in uveitis and disease activity","volume":"23","author":"Gheita","year":"2013","journal-title":"Mod Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"380405","DOI":"10.1155\/2014\/380405","article-title":"Expression of TNF-\u03b1, APRIL and BCMA in Beh\u00e7et\u2019s disease","volume":"2014","author":"Shaker","year":"2014","journal-title":"J Immunol Res"},{"key":"B25","first-page":"1078","article-title":"International study group for Behc\u00b8et\u2019s disease","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","journal-title":"Lancet"},{"issue":"3","key":"B26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"B27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10875-012-9820-y","article-title":"Soluble levels of osteopontin in patients with Beh\u00e7et\u2019s disease: association with disease activity and vascular involvement","volume":"33","author":"Bassyouni","year":"2013","journal-title":"J Clin Immunol"},{"issue":"2","key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/0019-5154.94273","article-title":"Serum lipid, lipoprotein and oxidatively modified low density lipoprotein levels in active or inactive patients with Beh\u00e7et\u2019s disease","volume":"57","author":"Cimen","year":"2012","journal-title":"Indian J Dermatol"},{"issue":"8","key":"B29","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1038\/jid.2010.114","article-title":"IL-17A has an important role in the acute attacks of Beh\u00e7et\u2019s disease","volume":"130","author":"Ekinci","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B30","first-page":"172","article-title":"Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer","volume":"53","author":"Johansen","year":"2006","journal-title":"Dan Med Bull"},{"issue":"7","key":"B31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1468-3083.2012.04570.x","article-title":"Plasma YKL-40: a potential biomarker for psoriatic arthritis?","volume":"27","author":"Jensen","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"B32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jdermsci.2011.06.012","article-title":"YKL-40 (chitinase 3-like-1) as a biomarker for psoriasis vulgaris and pustular psoriasis","volume":"64","author":"Imai","year":"2011","journal-title":"J Dermatol Sci"},{"issue":"3","key":"B33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0923-1811(95)00439-4","article-title":"Interleukin-6 (IL-6) in patients with Beh\u00e7et\u2019s disease","volume":"11","author":"Yamakawa","year":"1996","journal-title":"J Dermatol Sci"},{"issue":"7","key":"B34","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Beh\u00e7et patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"B35","first-page":"1299","article-title":"Serum YKL-40 and MDA levels in Beh\u00e7et disease","volume":"66","author":"Bilen","year":"2016","journal-title":"J Pak Med Assoc"},{"issue":"5","key":"B36","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.4049\/jimmunol.159.5.2161","article-title":"Interleukin-11 inhibits macrophage interleukin-12 production","volume":"159","author":"Leng","year":"1997","journal-title":"J Immunol"},{"issue":"8","key":"B37","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.4049\/jimmunol.157.8.3627","article-title":"Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production","volume":"157","author":"Trepicchio","year":"1996","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","article-title":"Gp130 and the interleukin-6 family of cytokines","volume":"15","author":"Taga","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"B40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/jir.2005.25.241","article-title":"IL-6 trans signaling: the in vivo consequences","volume":"25","author":"Jones","year":"2005","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"B41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat Med"},{"issue":"6","key":"B42","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1074-7613(01)00151-0","article-title":"IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation","volume":"14","author":"Hurst","year":"2001","journal-title":"Immunity"},{"issue":"4","key":"B43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2004.07.020","article-title":"TGF suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling","volume":"21","author":"Becker","year":"2004","journal-title":"Immunity"},{"issue":"2","key":"B44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1172\/JCI22433","article-title":"The IL-6R chain controls lung CD4 CD25 Treg development and function during allergic airway inflammation in vivo","volume":"115","author":"Doganci","year":"2005","journal-title":"J Clin Invest"},{"issue":"6","key":"B45","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.4049\/jimmunol.171.6.3202","article-title":"Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130","volume":"171","author":"Nowell","year":"2003","journal-title":"J Immunol"},{"issue":"8","key":"B46","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.4049\/jimmunol.173.8.5290","article-title":"Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6\/soluble IL-6 receptor trans-signaling","volume":"173","author":"Curnow","year":"2004","journal-title":"J Immunol"},{"issue":"9","key":"B47","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1164\/rccm.201404-0689OC","article-title":"Interleukin-26 in antibacterial host defense of human lungs. Effects on neutrophil mobilization","volume":"190","author":"Che","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"B48","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/gut.2007.130112","article-title":"The role of the novel Th17 cytokine IL-26 in intestinal inflammation","volume":"58","author":"Dambacher","year":"2009","journal-title":"Gut"},{"issue":"10","key":"B49","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.203","article-title":"Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease","volume":"40","author":"Kugathasan","year":"2008","journal-title":"Nat Genet"},{"issue":"7230","key":"B50","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nature07537","article-title":"A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity","volume":"457","author":"Cella","year":"2009","journal-title":"Nature"},{"issue":"9","key":"B51","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"issue":"2","key":"B52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/ng.275","article-title":"Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study","volume":"41","author":"Silverberg","year":"2009","journal-title":"Nat Genet"},{"key":"B53","first-page":"16","article-title":"The mode of action of cytokine inhibitors","volume":"65","author":"Arend","year":"2002","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"B54","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Beh\u00e7et\u2019s disease: soluble TNFR-75 as a biological marker of disease activity","volume":"24","author":"Turan","year":"1997","journal-title":"J Rheumatol"},{"issue":"10","key":"B55","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/art.1780351008","article-title":"Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases","volume":"35","author":"Cope","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"8","key":"B56","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/art.1780360812","article-title":"Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus","volume":"36","author":"Aderka","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"4","key":"B57","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/rheumatology\/39.4.432","article-title":"Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis","volume":"39","author":"Rooney","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"B58","first-page":"33","article-title":"[Soluble receptors of TNF-alpha in rheumatoid arthritis]","volume":"79","author":"Nasonov","year":"2001","journal-title":"Klin Med (Mosk)"},{"issue":"3","key":"B59","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5966\/sctm.2015-0179","article-title":"Soluble tumor necrosis factor receptor 1 released by skin-derived mesenchymal stem cells is critical for inhibiting Th17 cell differentiation","volume":"5","author":"Ke","year":"2016","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"B60","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/cei.12768","article-title":"Immunome\\olic biomarkers of inflammation in Beh\u00e7et\u2019s disease: relationship with epidemiological profile, disease activity and therapeutic regimens","volume":"184","author":"Cantarini","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"3 Suppl 77","key":"B61","first-page":"32","article-title":"Up-regulation of Th17 and related cytokines in Beh\u00e7et\u2019s disease corresponding to disease activity","volume":"31","author":"Na","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"B62","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.4049\/jimmunol.1202677","article-title":"Role of IL-22- and TNF-\u03b1-producing Th22 cells in uveitis patients with Beh\u00e7et\u2019s disease","volume":"190","author":"Sugita","year":"2013","journal-title":"J Immunol"},{"issue":"2","key":"B63","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/gene.2014","article-title":"Activation of the JAK\/STAT pathway in Beh\u00e7et\u2019s disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T14:24:52Z","timestamp":1719066292000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":63,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00200","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,27]]}}}